Skip to main content

Advertisement

Table 2 Fatty acid analysis of PC-3 cells that were supplemented with various fatty acids at the end of 48 hours of supplementation of various fatty acids

From: Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro

Fatty acids in PC-3 Composition percentage (%)
  Linolelaidic acid Linoleic acid γ-linolenic acid Arachidonic acid α-linolenic acid EPA DHA
Control 2.25 ± 0.01 0.14 ± 0.01 0.88 ± 0.03 1.22 ± 0.03 0.12 ± 0..01 N.D 0.71 ± 0.03
LA(50 μM) 0.05 ± 0.01*** 0.80 ± 0.10** 0.40 ± 0.08* 1.25 ± 0.19 0.09 ± 0.02 0.89 ± 0.11** 0.58 ± 0.06
LA(150 μM) 6.05 ± 0.08** 1.92 ± 0.38*** 0.42 ± 0.14* 0.88 ± 0.12* 5.58 ± 0.39*** 2.48 ± 0.34*** 3.02 ± 0.26**
GLA(25 μM) 1.62 ± 0.18* 0.19 ± 0.08 0.97 ± 0.08 15.29 ± 2.73*** 1.83 ± 0.37** N.D 0.50 ± 0.12
GLA(50 μM) 1.56 ± 0.10* 0.20 ± 0.02 1.08 ± 0.28 22.24 ± 0.31*** 4.87 ± 0.32*** N.D 0.53 ± 0.01
GLA(75 μM) 1.11 ± 0.05** 0.16 ± 0.06 0.76 ± 0.00 29.28 ± 0.52*** 10.98 ± 0.45*** N.D 0.35 ± 0.01*
AA(50 μM) 1.94 ± 0.04 0.08 ± 0.01** 0.09 ± 0.01*** 14.28 ± 0.44*** 0.08 ± 0.01 0.37 ± 0.01* 0.69 ± 0.09
AA(100 μM) 1.88 ± 0.04 0.08 ± 0.01** 0.08 ± 0.01*** 22.20 ± 0.63*** 0.07 ± 0.01 0.46 ± 0.01* 0.62 ± 0.09
ALA(50 μM) 0.60 ± 0.08*** 0.45 ± 0.08* 0.72 ± 0.24 1.49 ± 0.35* 0.51 ± 0.13* 1.98 ± 0.42** 4.83 ± 0.68**
ALA(150 μM) 0.66 ± 0.27*** 1.32 ± 0.20*** 0.82 ± 0.33 1.13 ± 0.13 2.13 ± 0.18** 1.64 ± 0.40** 2.50 ± 0.35**
EPA(50 μM) 2.46 ± 0.65 0.26 ± 0.05* 1.35 ± 0.12* 1.17 ± 0.31 0.11 ± 0.005 2.78 ± 0.03*** 9.56 ± 0.38***
EPA(100 μM) 1.79 ± 0.13* 0.24 ± 0.03* 1.16 ± 0.02* 1.37 ± 0.05* 0.14 ± 0.03 5.64 ± 1.80*** 14.11 ± 2.57***
DHA(50 μM) 1.98 ± 0.10* 0.24 ± 0.02* 1.08 ± 0.03* 1.30 ± 0.02 N.D N.D 11.17 ± 1.08***
DHA 100 μM 1.88 ± 0.04* 0.21 ± 0.02* 0.99 ± 0.09 1.32 ± 0.07 0.11 ± 0.02 0.11 ± 0.01* 19.08 ± 0.06***
  1. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control.